Clinical Research Directory
Browse clinical research sites, groups, and studies.
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
Sponsor: VA Office of Research and Development
Summary
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
Official title: Addition of F18-Piflufolastat PET/CT to Cross-Sectional Imaging for the Staging and Management of Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
90
Start Date
2024-09-19
Completion Date
2028-09-30
Last Updated
2025-07-23
Healthy Volunteers
No
Conditions
Locations (1)
Miami VA Healthcare System, Miami, FL
Miami, Florida, United States